According to the models built, both drugs were able to modulate common pathways through their common off-target binding, but ibrutinib modulated more strongly proteins involved in hypertension, such as CXCR3 and CFTR (Fig. 3a and b). This evidence concerns the gene CXCR3 and Hypertension.